Switch to: Citations

Add references

You must login to add references.
  1. Overcoming Entrenched Disagreements: the Case of Misoprostol for Post‐Partum Haemorrhage.Narcyz Ghinea, Wendy Lipworth, Miles Little, Ian Kerridge & Richard Day - 2013 - Developing World Bioethics 15 (1):48-54.
    The debate about whether misoprostol should be distributed to low resource communities to prevent post-partum haemorrhage, recognised as a major cause of maternal mortality, is deeply polarised. This is in spite of stakeholders having access to the same evidence about the risks and benefits of misoprostol. To understand the disagreement, we conducted a qualitative analysis of the values underpinning debates surrounding community distribution of misoprostol. We found that different moral priorities, epistemic values, and attitudes towards uncertainty were the main factors (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  • Ethics & Evidence in Medical Debates: The Case of Recombinant Activated Factor VII.Narcyz Ghinea, Wendy Lipworth, Ian Kerridge, Miles Little & Richard O. Day - 2014 - Hastings Center Report 44 (2):38-45.
    While ethics and evidence‐based medicine are often viewed as separate domains of inquiry and practice, what we know influences what we can ethically justify doing, and what we see as our moral obligations shapes the way we interpret evidence. The boundaries between the moral and epistemic spheres become particularly blurred when the health of people is at stake and even more so when no “officially” recommended medical intervention is available to help a patient in need. The treatment of major hemorrhages (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  • Off-Label Prescribing: A Call for Heightened Professional and Government Oversight.Rebecca Dresser & Joel Frader - 2009 - Journal of Law, Medicine and Ethics 37 (3):476-486.
    Under current U.S. law, physicians may prescribe drugs and devices in situations not covered on the label approved by the Food and Drug Administration. Those supporting this system say that requiring FDA approval for off-label uses would unnecessarily impede the delivery of benefits to patients. Patients do benefit from off-label prescribing that is supported by sound scientific and medical evidence. In the absence of such evidence, however, off-label prescribing can expose patients to risky and ineffective treatments. The medical community and (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   14 citations  
  • Off-Label Prescribing: A Call for Heightened Professional and Government Oversight.Rebecca Dresser & Joel Frader - 2009 - Journal of Law, Medicine and Ethics 37 (3):476-486.
    Off-label prescribing is an integral part of contemporary medicine. Many patients benefit when they receive drugs or devices under circumstances not specified on the label approved by the Food and Drug Administration. An off-label use may provide the best available intervention for a patient, as well as the standard of care for a particular health problem. In oncology, pediatrics, geriatrics, obstetrics, and other practice areas, patient care could not proceed without off-label prescribing. When scientific and medical evidence justify off-label uses, (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   14 citations